Health-care companies ticked up after a generally strong round of earnings. Hospital chain HCA Healthcare boosted its full-year growth outlook after logging higher profit and revenue in the third ...

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent ...

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

Sanofi (SNY) stock gains as the company posts a Q3 beat for 2025, driven mainly by Dupixent, an asthma therapy it markets ...

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

Sanofi said new medicine generated sales of 1 billion euros, up 57% from the same period last year. It said that Dupixent sales jumped 26% to 4.2 billion euros, which allowed the company to offset a 7 ...

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its ...